About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
How I Use CAR T-Cells in Lymphoma
By
MyCancerHaven
FEATURING
Ravi Vij
,
Abhinav Deol
By
MyCancerHaven
FEATURING
Ravi Vij
,
Abhinav Deol
56 views
April 10, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
37:21
Amgen Sponsorship
New Approval for Frontline Consolidation in Patients with CD19-posit…
Feat.
J. Mccloskey
Featured Video
11:12
Stemline
A proven CD123 targeted therapy for BPDCN
Feat.
H. Erba
Related Content
AUTOPLAY
ON
Moffitt Cancer Center
2024 Cell Coast Conference
Fri, Oct 25, 2024
13:07
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
Feat.
J. Chavez
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
35:27
Louisville Hematology Highlights
Updates on Management of DLBCL
Feat.
J. Leonard
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
20:34
UChicago Medicine
Sequencing of Bispecifics With Other Therapies in DLBCL
Feat.
E. Budde
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
Feat.
R. Gale
08:23
Total Health
R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment
Feat.
J. Chandler,
B. Randolph,
M. Onciu
09:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…
Feat.
J. Westin
14:01
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
Feat.
M. Gomes da Silva
30:07
Dipenkumar Modi
Current Management of DLBCL From Frontline to Relapsed Disease
45:27
University of Colorado Department of Medicine
Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…
Feat.
J. Gutman
22:36
UChicago Medicine
Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…
Feat.
A. Cooper
15:26
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
Feat.
A. Lazaryan
25:22
Integrity CE
Treatment Updates and Management of Non-Hodgkin Lymphomas
Feat.
D. Wallace,
M. Cortese
20:18
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…
Feat.
M. Hamilton
08:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…
Feat.
R. Bansal
62:02
UChicago Medicine
New Treatment Strategies in DLBCL
Feat.
L. Sehn
04:08
GRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
25:06
Scripps Health
Update in the Treatment of R/R DLBCL
Feat.
C. Andreadis
28:10
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell To…
Feat.
D. Reeves
